Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care

2400 - Germline mutation status and therapy response in patients with triple-negative breast cancer (TNBC): Results of the GeparOcto study

Date

22 Oct 2018

Session

Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care

Presenters

Esther Pohl

Citation

Annals of Oncology (2018) 29 (suppl_8): viii58-viii86. 10.1093/annonc/mdy270

Authors

E. Pohl1, A. Schneeweiss2, J. Hauke1, V. Moebus3, J. Furlanetto4, C. Denkert5, P.A. Fasching6, C. Hanusch7, H. Tesch8, N. Weber-Lassalle1, V. Müller9, K. Rhiem1, M. Untch10, K. Luebbe11, B. Lederer4, C. Jackisch12, V. Nekljudova4, R.K. Schmutzler1, E. Hahnen1, S. Loibl4

Author affiliations

  • 1 Center For Familial Breast And Ovarian Cancer And Center For Integrated Oncology (cio), Medical Faculty, University of Cologne and University Hospital Cologne, 50931 - Cologne/DE
  • 2 National Center For Tumor Diseases, University of Heidelberg, 69115 - Heidelberg/DE
  • 3 Department Of Gynecology And Obstetrics, Klinikum Frankfurt Höchst, Academic Hospital of the Goethe University Frankfurt, Frankfurt/DE
  • 4 Gbg, German Breast Group Forschungs GmbH, 63263 - Neu-Isenburg/DE
  • 5 Institute Of Pathology, Charité - Universitätsmedizin Berlin, 10117 - Berlin/DE
  • 6 Department Of Gynecology And Obstetrics, University Hospital Erlangen, 91054 - Erlangen/DE
  • 7 Frauenklinik, Rotkreuzklinikum, Munich/DE
  • 8 Hämatologisch-onkologische Gemeinschaftspraxis, Bethanien-Krankenhaus, Frankfurt/DE
  • 9 Department Of Gynecology, Hamburg-Eppendorf University Medical Center, Hamburg/DE
  • 10 Department Of Gynecology And Obstetrics, Helios Klinikum Berlin-Buch, Berlin/DE
  • 11 Breast Center, Diakovere Henriettenstift, Hannover/DE
  • 12 Department Of Obstetrics And Gynecology, Sana Klinikum Offenbach GmbH, 63069 - Offenbach/DE
More

Resources

Abstract 2400

Background

The phase III neoadjuvant GeparOcto trial (NCT02125344) randomized patients with triple negative breast cancer (TNBC) to receive treatment with intensified dose-dense epirubicin (E), paclitaxel (P), and cyclophosphamide (C; iddEPC) or weekly paclitaxel/liposomal doxorubicin (PM), plus carboplatin (Cb). Data on germline mutational analysis of patients with TNBC and the correlation with pathological complete response (pCR ypT0/is ypN0) were analysed.

Methods

NGS-based germline mutational analysis of BRCA1/2 and further 16 BC predisposition or candidate predisposition genes was carried out in 393 patients (iddEPC n = 194, PMCb n = 199). Deleterious (IARC class 4/5) variants were validated by Sanger sequencing. Detection of copy number variations (CNV) was carried out using an in-house CNV detection tool and established open access tools. Validation of CNVs was performed by either multiplex ligation-dependent probe amplification or real-time PCR.

Results

Overall, 69 of 393 (17.6%) patients carry pathogenic mutations in the BRCA1/2 genes. In 324 BRCA1/2-negative patients, 30 patients carry mutations in at least one of the 16 further analysed genes (9.3%). Of those, two patients carry mutations in two genes (ATM/CHEK2, PALB2/XRCC2) and 28 carry mutations in one gene (n = 2 BARD1, n = 5 BRIP1, n = 1 CHEK2, n = 9 FANCM, n = 1 NBN, n = 8 PALB2, n = 1 RAD50, n = 1 RAD51C); no mutations were found in CDH1, MRE11A, PTEN, RAD51D, STK11, and TP53). Overall patients with a BRCA1/2 mutation had a pCR of 69.6% vs 46.0% without a mutation (p < 0.001). In the iddETC group, patients with a BRCA1/2 mutation had a pCR of 64.7% vs 45.0% without a mutation (p = 0.040); in the PMCb arm, patients with a BRCA1/2 mutation had a pCR of 74.3% vs 47.0% without a mutation (p = 0.005).

Conclusions

Our data confirm that BRCA1/2 germline mutations represent a predictive biomarker for the achievement of pCR following neoadjuvant anthracycline-taxane-containing chemotherapy for TNBC.

Clinical trial identification

NCT02125344.

Legal entity responsible for the study

German Breast Group (GBG).

Funding

German Breast Group (GBG).

Editorial Acknowledgement

Disclosure

A. Schneeweiss: Honoraria: Roche, Celgene, AstraZeneca, Novartis, and Pfizer during the past 2 years. C. Hanusch: Consulting or advisory role: Novartis, Roche, Amgen, and Celgene during the past 2 years; Speakers’ bureau: Novartis, Roche, Amgen, Pfizer, and Celgene during the past 2 years. V. Müller: Honoraria: Amgen, AstraZeneca, Daiichi Sankyo, Eisai, Pfizer, Novartis, Roche, and Teva during the past two years; Consulting or advisory role: Hexal, Roche, Pfizer, Amgen, Daiichi Sankyo, Nektar, and Eisai during the past 2 years; Travel, accommodation, or other expenses paid or reimbursed: Roche and Pfizer during the past 2 years. K. Luebbe: Consulting or advisory role: Roche and Novartis during the past 2 years. S. Loibl: Honoraria: Pfizer and Roche during the past 2 years (institution); Consulting or advisory role: Novartis, Pfizer, Roche, and SeaGen during the past 2 years (institution); Research project funding: Abbvie, Amgen, AstraZeneca, Celgene Novartis, Pfizer, Roche, SeaGen, Teva, and Vifor during the past 2 years (institution). All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings